AIM ImmunoTech's New Cancer Patent Sparks a 34% Rally — But Can a Sub-$10 Million Company Cash In on a $32 Billion Drug Market?

Shares of AIM ImmunoTech surged 34.3% to $0.35 on an otherwise red-tape Monday after the company announced the U.S. Patent and Trademark Office granted it exclusive rights to combine its experimental drug Ampligen with Merck's blockbuster cancer treatment pembrolizumab (sold as Keytruda) across a wide range of tumor types. The patent doesn't mean the combination works — it means no one else can sell it if it does.

• The Patent Covers a Lot of Ground, But the Company Is Tiny. The new patent covers the combined use of Ampligen with pembrolizumab across cancer types including pancreatic, ovarian, colorectal, breast, lung, and others.

The broadest claim covers the two drugs given together or at different times when the combination has a greater effect than either treatment alone. That's a wide net — but AIM's market cap sat around just $8 million before today's pop. The company generated only $88,000 in trailing-twelve-month revenue, with an operating loss of $11.7 million. A patent is only as valuable as the product it protects.

• It Links AIM to Keytruda's Massive Ecosystem — At Least on Paper. The global Keytruda market was valued at roughly $31.4 billion in 2025 and is projected at $32.7 billion in 2026.

Combined Keytruda sales grew 12% in Q1 2026. Owning an exclusive patent on combining your drug with the world's best-selling cancer therapy is a potential licensing lever — but AIM is not affiliated with, sponsored by, or endorsed by Merck. There is no deal in hand.

• Real Clinical Data Is Months Away — and Will Make or Break the Story. AIM expects to begin primary endpoint analysis of its pancreatic cancer trial in December 2026, with topline results anticipated in Q1 2027.

An earlier patient program showed Ampligen-treated patients had median survival of 19.7 months versus 8.6 months for standard care — promising but not from a controlled trial. The patent expires December 2039, giving AIM a 13-year runway if regulators ever approve the drug.

• The Stock Is Volatile and Cash-Burning. Over the past 12 months, the stock has lost 95.4%.

Analysts project the company will remain unprofitable, with an estimated $37 million in net losses over the next three years. Today's spike is dramatic in percentage terms but adds only about $2.7 million in market value. For shareholders, the patent is a necessary building block — not a foundation.